Abstract 2237P
Background
This trial explores the clinical efficacy and safety of AVE, CET and IRI for treatment refractory MSS mCRC. We aim at characterizing the immune response for biomarker discovery through associated translational research.
Methods
MSS, chemorefractory (anti-EGFR refractory if RAS wt) mCRC patients (pts) were enrolled (RAS wt: 28 pts, RAS mut: 27 pts) and treated with CET and IRI from week 1(W1) and AVE from W3. Clinical objectives (safety, tumor response, disease control rate (DCR), PFS and OS) were presented separately. Exploratory endpoints include predictive efficacy biomarkers (immunoscore (IS), immune tumor microenvironment, gene expression profile (GEP), ctDNA) and modification overtime. Multiplex immunofluorescence (MIF), RNAseq and ctDNA analyses were done (sequential metastasis biopsies and plasma samples at W0, W3, W11). CD3, CD8, CD45RO, PD1, PD-L1cells densities were quantified. RNA-seq data were used to perform several analyses (DESeq2, GSEA, deconvolution, gene ontology). OncoSELECT panel (58 genes) was used to follow ctDNA variation over time (mean variant allele frequency).
Results
Among 55 treated pts, 95 biopsies (W0: 39, W3: 29, W11: 27) were available for MIF (table: W0 results). On 23 pts (1st stage), upregulation of adaptive immune response signature was associated with tumor shrinkage, PFS>6 and OS>12 months (p. adj= 0.00). Few modifications of immune cells and GEP were observed overtime (W0, W3, W11). ctDNA decrease (>10%) was associated with tumor response (p=0.04) and PFS (6.6 vs 3.4 months, p=0.08). Table: 2237P
| Characteristics | IS (CD3/CD8) high | CD3/PD1 high | CD3/CD8/CD45RO/PD1 high |
| High/others:pts | 10/29 | 10/29 | 8/31 |
| RAS-wt/RAS-mut:OR, p-v | 1.39, p=0.73 | 0.82, p=0.99 | 0.83, p=0.99 |
| Tumor shrinkage: OR, p-v | 8.32, p=0.00 | 4.50, p=0.05 | 9.54, p=0.00 |
| DCR:OR, p-v | 8.02, p=0.05 | 3.16, p=0.26 | 5.55, p=0.12 |
| PFS:HR, p-v | 0.29, p=0.00 | 0.28, p=0.00 | 0.43, p=0.03 |
| OS:HR, p-v | 0.62, p=0.19 | 0.26, p=0.00 | 0.47, p=0.06 |
Conclusions
Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.
Clinical trial identification
NCT03608046.
Editorial acknowledgement
Legal entity responsible for the study
Cliniques Universitaires Saint-Luc (Pr. MD. PhD. Marc van den Eynde).
Funding
Merck Serono.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Presenter: Pau Mascaró Baselga
Session: Poster session 07
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07